Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors

Shilajit D Kundu, Darren R. Feldman, Brett S. Carver, Amit Gupta, George J. Bosl, Robert J. Motzer, Dean F. Bajorin, Joel Sheinfeld*

*Corresponding author for this work

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. Materials and Methods Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. Results No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5% vs 6%, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57% vs 34%, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95% CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95% CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. Conclusions Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalJournal of Urology
Volume193
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Induction Chemotherapy
Teratoma
Etoposide
Lymph Node Excision
Cisplatin
Drug Therapy
Bleomycin
Neoplasms
Disease-Free Survival
Nonseminomatous germ cell tumor
Recurrence
Selection Bias
Residual Neoplasm
Multivariate Analysis

Keywords

  • neoplasms, germ cell and embryonal
  • teratoma
  • testicular neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Kundu, Shilajit D ; Feldman, Darren R. ; Carver, Brett S. ; Gupta, Amit ; Bosl, George J. ; Motzer, Robert J. ; Bajorin, Dean F. ; Sheinfeld, Joel. / Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. In: Journal of Urology. 2015 ; Vol. 193, No. 2. pp. 513-518.
@article{a65fad50953e4b9a9a3b033bb89ddf37,
title = "Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors",
abstract = "Purpose Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. Materials and Methods Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. Results No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5{\%} vs 6{\%}, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57{\%} vs 34{\%}, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95{\%} CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95{\%} CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. Conclusions Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.",
keywords = "neoplasms, germ cell and embryonal, teratoma, testicular neoplasms",
author = "Kundu, {Shilajit D} and Feldman, {Darren R.} and Carver, {Brett S.} and Amit Gupta and Bosl, {George J.} and Motzer, {Robert J.} and Bajorin, {Dean F.} and Joel Sheinfeld",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.juro.2014.08.081",
language = "English (US)",
volume = "193",
pages = "513--518",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. / Kundu, Shilajit D; Feldman, Darren R.; Carver, Brett S.; Gupta, Amit; Bosl, George J.; Motzer, Robert J.; Bajorin, Dean F.; Sheinfeld, Joel.

In: Journal of Urology, Vol. 193, No. 2, 01.02.2015, p. 513-518.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors

AU - Kundu, Shilajit D

AU - Feldman, Darren R.

AU - Carver, Brett S.

AU - Gupta, Amit

AU - Bosl, George J.

AU - Motzer, Robert J.

AU - Bajorin, Dean F.

AU - Sheinfeld, Joel

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Purpose Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. Materials and Methods Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. Results No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5% vs 6%, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57% vs 34%, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95% CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95% CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. Conclusions Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.

AB - Purpose Patients with good risk nonseminomatous germ cell tumors received induction chemotherapy with 4 cycles of etoposide and cisplatin (EPx4) or 3 cycles of bleomycin, etoposide and cisplatin (BEPx3). We report the histological results at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy in patients treated with etoposide and cisplatin or bleomycin, etoposide and cisplatin for good risk nonseminomatous germ cell tumors. Materials and Methods Post-chemotherapy retroperitoneal lymph node dissection was performed in 579 patients after induction chemotherapy. Of these patients 505 were treated with EPx4 and 74 were treated with BEPx3 or BEPx4. Clinical and pathological features are reported. Results No difference in the frequency of viable residual cancer was observed with bleomycin, etoposide and cisplatin vs etoposide and cisplatin (5% vs 6%, respectively, p=not significant). Teratoma was more prevalent in the bleomycin, etoposide and cisplatin group vs etoposide and cisplatin group (57% vs 34%, respectively, p <0.001). On multivariate analysis patients who received induction bleomycin, etoposide and cisplatin had a twofold greater risk of harboring teratoma at post-chemotherapy retroperitoneal lymph node dissection (OR 2.0; 95% CI 1.0, 4.0; p=0.04). When excluding patients from analysis who received BEPx4, those who received BEPx3 still had a 3.7-fold increased risk of teratoma in the retroperitoneum (OR 3.7; 95% CI 1.5, 8.9; p=0.004). Relapse-free and disease specific survival was not different between the 2 regimens. Conclusions Viable cancer was equally uncommon after treatment with both regimens. Overall, relapse-free and disease specific survival did not differ between the groups. The discrepancy between regimens in the frequency of teratoma is not explained but may be due to an unrecognized selection bias rather than an effect of the regimen.

KW - neoplasms, germ cell and embryonal

KW - teratoma

KW - testicular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84920725039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920725039&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2014.08.081

DO - 10.1016/j.juro.2014.08.081

M3 - Article

VL - 193

SP - 513

EP - 518

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -